Literature DB >> 33118146

Comparison of One and Three Intraventricular Injections of Cardiac Progenitor Cells in a Murine Model of Chronic Ischemic Cardiomyopathy.

Yiru Guo1, Yibing Nong1, Qianhong Li1, Alex Tomlin1, Arunpreet Kahlon1, Anna Gumpert1, Jan Slezak2, Xiaoping Zhu1, Roberto Bolli3.   

Abstract

Repeated doses of c-kit+ cardiac progenitor cells (CPCs) are superior to a single dose in improving LV function in rats with old myocardial infarction (MI). However, this concept needs testing in different species to determine whether it is generalizable. We used a new murine model of chronic ischemic cardiomyopathy whose unique feature is that cell therapy was started late (3 months) after MI. Mice received three echo-guided intraventricular infusions, 5 weeks apart, of vehicle, CPCs × 1, or CPCs × 3. Echocardiography demonstrated that the single-dose group exhibited improved LV ejection fraction (EF) after the 1st infusion (CPCs), but not after the 2nd and 3rd (vehicle). In contrast, in the multiple-dose group LVEF continued to improve, so that the final value was greater than in vehicle or single-dose groups (P < 0.05). Hemodynamic studies showed that compared with vehicle, both preload-dependent and preload-independent functional parameters were significantly increased in the multiple-dose group but not in the single-dose group. Thus, two independent methods of functional assessment (echocardiography and hemodynamic studies) consistently demonstrated the superiority of three doses of CPCs vs. one dose. Compared with the single-dose group, the multiple-dose group exhibited less LV hypertrophy, as evidenced by a greater reduction in LV/body weight ratio and cardiomyocyte cross-sectional area. Furthermore, unlike the single dose, three CPC doses reduced myocardial inflammatory cells in the risk region. This is the first study of echo-guided intraventricular infusion of CPCs in mice with chronic ischemic cardiomyopathy. The results demonstrate that the beneficial effects of three CPC doses are greater than those of one dose, supporting the concept that multiple treatments are necessary to properly evaluate cell therapy. Our findings indicate that this concept applies not only to rat models but also to murine models. The generalizability of this strategy greatly enhances its importance and provides a rationale for large animal studies. Graphical abstract.

Entities:  

Keywords:  Cardiac progenitor cell; Cell therapy; Chronic ischemic cardiomyopathy; Multiple doses; Reperfused myocardial infarction

Mesh:

Year:  2020        PMID: 33118146      PMCID: PMC8043991          DOI: 10.1007/s12015-020-10063-0

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  18 in total

1.  Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models.

Authors:  Qianhong Li; Yiru Guo; Qinghui Ou; Ning Chen; Wen-Jian Wu; Fangping Yuan; Erin O'Brien; Tao Wang; Li Luo; Gregory N Hunt; Xiaoping Zhu; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2011-04-24       Impact factor: 17.165

Review 2.  American Society of Echocardiography recommendations for use of echocardiography in clinical trials.

Authors:  John S Gottdiener; James Bednarz; Richard Devereux; Julius Gardin; Allan Klein; Warren J Manning; Annitta Morehead; Dalane Kitzman; Jae Oh; Miguel Quinones; Nelson B Schiller; James H Stein; Neil J Weissman
Journal:  J Am Soc Echocardiogr       Date:  2004-10       Impact factor: 5.251

3.  Activation of the complement system by recombinant tissue plasminogen activator.

Authors:  W R Bennett; D H Yawn; P J Migliore; J B Young; C M Pratt; A E Raizner; R Roberts; R Bolli
Journal:  J Am Coll Cardiol       Date:  1987-09       Impact factor: 24.094

4.  Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction.

Authors:  Yiru Guo; Marcin Wysoczynski; Yibing Nong; Alex Tomlin; Xiaoping Zhu; Anna M Gumpert; Marjan Nasr; Senthikumar Muthusamy; Hong Li; Michael Book; Abdur Khan; Kyung U Hong; Qianhong Li; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2017-02-16       Impact factor: 17.165

5.  The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene.

Authors:  Y Guo; W K Jones; Y T Xuan; X L Tang; W Bao; W J Wu; H Han; V E Laubach; P Ping; Z Yang; Y Qiu; R Bolli
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

6.  A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice.

Authors:  Kyung U Hong; Qian-Hong Li; Yiru Guo; Nikita S Patton; Afsoon Moktar; Aruni Bhatnagar; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2013-04-03       Impact factor: 17.165

7.  Repeated Cell Therapy: A Paradigm Shift Whose Time Has Come.

Authors:  Roberto Bolli
Journal:  Circ Res       Date:  2017-02-08       Impact factor: 17.367

8.  Demonstration of an early and a late phase of ischemic preconditioning in mice.

Authors:  Y Guo; W J Wu; Y Qiu; X L Tang; Z Yang; R Bolli
Journal:  Am J Physiol       Date:  1998-10

9.  Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function.

Authors:  Buddhadeb Dawn; Yiru Guo; Arash Rezazadeh; Yiming Huang; Adam B Stein; Greg Hunt; Sumit Tiwari; Jai Varma; Yan Gu; Sumanth D Prabhu; Jan Kajstura; Piero Anversa; Suzanne T Ildstad; Roberto Bolli
Journal:  Circ Res       Date:  2006-03-23       Impact factor: 17.367

10.  c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart.

Authors:  Kyung U Hong; Yiru Guo; Qian-Hong Li; Pengxiao Cao; Tareq Al-Maqtari; Bathri N Vajravelu; Junjie Du; Michael J Book; Xiaoping Zhu; Yibing Nong; Aruni Bhatnagar; Roberto Bolli
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

View more
  6 in total

1.  Effect of intravenous cell therapy in rats with old myocardial infarction.

Authors:  Xian-Liang Tang; Marcin Wysoczynski; Anna M Gumpert; Yan Li; Wen-Jian Wu; Hong Li; Heather Stowers; Roberto Bolli
Journal:  Mol Cell Biochem       Date:  2021-11-16       Impact factor: 3.396

2.  PU.1 inhibition does not attenuate cardiac function deterioration or fibrosis in a murine model of myocardial infarction.

Authors:  Yibing Nong; Yiru Guo; Qinghui Ou; Anna Gumpert; Alex Tomlin; Xiaoping Zhu; Roberto Bolli
Journal:  Mol Cell Biochem       Date:  2022-09-17       Impact factor: 3.842

3.  The sad plight of cell therapy for heart failure: causes and consequences.

Authors:  Roberto Bolli; Xian-Liang Tang
Journal:  J Cardiovasc Aging       Date:  2022-03-02

4.  Single dose of synthetic microRNA-199a or microRNA-149 mimic does not improve cardiac function in a murine model of myocardial infarction.

Authors:  Yibing Nong; Yiru Guo; Anna Gumpert; Qianhong Li; Alex Tomlin; Xiaoping Zhu; Roberto Bolli
Journal:  Mol Cell Biochem       Date:  2021-07-21       Impact factor: 3.396

5.  Effects of Heme Oxygenase-1 on c-Kit-Positive Cardiac Cells.

Authors:  Qianhong Li; Chandrashekhar Dasari; Ding Li; Asma Arshia; Ahmed Muaaz Umer; Mohamed Riad Abdelgawad Abouzid; Yiru Guo; Roberto Bolli
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

Review 6.  Cell therapy in patients with heart failure: a comprehensive review and emerging concepts.

Authors:  Roberto Bolli; Mitesh Solankhi; Xiang-Liang Tang; Arunpreet Kahlon
Journal:  Cardiovasc Res       Date:  2022-03-16       Impact factor: 10.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.